Compare AbbVie Inc (ABBV) vs Applied Materials, Inc. (AMAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Applied Materials, Inc. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Applied Materials, Inc. trades at $570 (market cap $440.25B). The key difference: AbbVie Inc and Applied Materials, Inc. are close in size by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | AMAT | |
|---|---|---|
Market Cap | $449.91B | $440.25B |
Sector | Health | Technology |
52-Week High | $261.07 | $723.00 |
52-Week Low | $184.85 | $156.25 |
Enterprise Value | $513.38B | $439.28B |
Dividend Yield | 2.72% | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Applied Materials (AMAT) trades at $592.79, down 1.78% on the day, amid a broader bullish technical trend. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.86 surpassing the $2.68 estimate. Strong profitability is evident with a net income margin of 29.31% and ROE of 39.69%. Recent news highlights the company's positioning in the AI-driven semiconductor equipment boom, with the CEO calling it 'the greatest time in the history of our industry' (CNBC, 2026-05-28).
The outlook remains positive, supported by robust analyst sentiment (76.92% buy ratings) and a consensus price target of $622.57, offering potential upside. Key risks include high valuation multiples (P/E of 55.77) and dependence on sustained semiconductor capital expenditure cycles. The stock presents an opportunity for growth investors aligned with the AI infrastructure theme, but requires monitoring of execution and market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →
